Core Viewpoint - The company Shijiazhuang Pharmaceutical Group (02005) is experiencing a significant decline in expected profits for the fiscal year 2025, projecting a decrease of 45%-60% compared to the previous year's profit of 1.061 billion HKD [1] Group 1 - The company's stock price fell over 5%, currently trading at 2.66 HKD with a trading volume of 52.9044 million HKD [1] - The anticipated profit decline is primarily attributed to a lack of large-scale epidemics in 2025, which is expected to reduce the demand for intravenous infusions and other pharmaceuticals [1] - The expansion of various forms of volume-based procurement and intensified competition in both domestic and international markets are contributing to ongoing pricing pressures [1] Group 2 - The revenue from the injection of bromhexine hydrochloride ampoules is expected to decrease as it will no longer be sold through the national drug collection system [1]

Core Viewpoint - The company Shijiazhuang Pharmaceutical Group (02005) is experiencing a significant decline in stock price, dropping over 7% following the announcement of a projected profit decrease for the fiscal year 2025, which is expected to fall by 45%-60% compared to the previous year's profit of 1.061 billion HKD [1] Group 1: Financial Performance - The company anticipates a profit decline for the fiscal year 2025, projecting earnings to decrease by 45%-60% from the previous year's 1.061 billion HKD [1] - The expected decline is attributed to a lack of large-scale epidemics in 2025, which will lead to decreased sales of pharmaceuticals due to reduced market demand [1] Group 2: Market Conditions - The first quarter of 2024 saw a surge in demand for intravenous infusions and other pharmaceuticals due to a domestic flu outbreak, but this demand is not expected to continue into 2025 [1] - The expansion of various forms of bulk purchasing, including national and local drug procurement, is expected to exert continuous price pressure on the company [1] - Increased competition within the domestic and international pharmaceutical industry is contributing to the ongoing pricing challenges faced by the company [1] Group 3: Product-Specific Issues - The revenue from the product Ambroxol Hydrochloride Injection is expected to decline as it will no longer be sold through national drug procurement channels [1]

Core Viewpoint - The company, Stone Four Pharmaceutical Group, anticipates a significant decline in profit attributable to equity holders for the fiscal year ending December 31, 2025, projecting a decrease of 45% to 60% compared to the profit of HKD 1.061 billion for the fiscal year ending December 31, 2024 [1] Group 1: Profit Forecast - The estimated profit decline is primarily attributed to a decrease in revenue due to several factors [1] - The first factor is the lack of large-scale epidemics in the domestic market after a surge in demand for intravenous infusions and other pharmaceuticals during the first quarter of 2024 due to a flu outbreak [1] - The second factor involves the expansion of various forms of bulk procurement, including national and local alliance drug procurement, which has intensified price pressure due to increased competition in the domestic and international markets [1] - The third factor is a reduction in revenue from the sales of Ambroxol Hydrochloride Injection due to its exclusion from national drug procurement [1]

Core Viewpoint - The company, 石四药集团, anticipates a decline of approximately 45% to 60% in profit attributable to equity holders for the year ending December 31, 2025, compared to HKD 1.061 billion for the year ending December 31, 2024 [1] Group 1: Profit Forecast - The estimated decline in profit is primarily due to a decrease in revenue caused by several factors, including the lack of large-scale epidemics in the domestic market and healthcare cost control measures leading to reduced drug sales [1] - The company expects that the expansion of various forms of bulk purchasing, including national and local drug procurement, along with intensified competition, will continue to exert price pressure [1] - Revenue from the product, 盐酸溴己新安瓿注射液, has decreased as it is no longer sold through national drug procurement [1] Group 2: Financial Health and Strategy - Despite the anticipated decline in profit, the company's financial position and cash flow remain robust [1] - The company has been focusing on product diversification in recent years, enhancing sales of oral formulations and active pharmaceutical ingredients to optimize its product mix [1] - The company is actively taking appropriate measures to seek improvements in performance, while closely monitoring the situation and responding in a timely manner as it progresses into 2026 [1]

Core Viewpoint - The company, Stone Four Pharmaceutical Group, anticipates a significant decline in profit attributable to equity holders, projecting a decrease of approximately 45% to 60% compared to HKD 1.061 billion for the year ending December 31, 2024 [1] Group 1: Profit Forecast - The estimated decline in profit is primarily due to a decrease in revenue driven by several factors, including the absence of large-scale epidemics and healthcare cost control measures leading to reduced drug sales [1] - The company expects that the absence of major epidemics, which previously boosted demand for intravenous infusions and other medications, will negatively impact sales for the year ending December 31, 2025 [1] - Increased price pressure from expanded volume-based procurement initiatives and intensified competition in both domestic and international markets is also contributing to the anticipated revenue decline [1] Group 2: Financial Health and Strategy - Despite the expected decline in profit, the company's financial position and cash flow remain robust [1] - The company has been focusing on product diversification in recent years, enhancing sales of oral formulations and active pharmaceutical ingredients to optimize its product mix [1] - The company is actively taking appropriate measures to seek improvements in performance, while closely monitoring the situation and responding in a timely manner as it progresses into 2026 [1]

Core Viewpoint - The company reported a significant decline in revenue and profit for the nine months ending September 30, 2025, primarily due to decreased sales in intravenous infusion and ampoule injection products, alongside intensified price pressures from expanded procurement initiatives and increased competition in the industry [1] Financial Performance - The company's unaudited revenue for the nine months ending September 30, 2025, was approximately HKD 3.102 billion, representing a year-on-year decrease of 31.6% [1] - The unaudited gross profit for the same period was approximately HKD 1.294 billion, down 46.1% year-on-year, with a gross profit margin of 41.7%, a decline of 11.3 percentage points compared to the previous year [1] - The unaudited profit attributable to shareholders for the nine months was approximately HKD 399 million, reflecting a year-on-year decrease of 56.6% [1]

Core Viewpoint - The company reported a significant decline in revenue and profit for the nine months ending September 30, 2025, primarily due to decreased sales in intravenous infusion and ampoule injection products, alongside intensified price pressures from expanded procurement initiatives and increased competition in the industry [1] Financial Performance - The company's unaudited revenue for the nine months was approximately HKD 3.102 billion, representing a year-on-year decrease of 31.6% [1] - The unaudited gross profit for the same period was approximately HKD 1.294 billion, down 46.1% year-on-year, with a gross profit margin of 41.7%, a decline of 11.3 percentage points compared to the previous year [1] - The unaudited profit attributable to shareholders for the nine months was approximately HKD 399 million, reflecting a year-on-year decrease of 56.6% [1]